Armando Anido - Jan 26, 2022 Form 4 Insider Report for Zynerba Pharmaceuticals, Inc. (ZYNE)

Role: Chairman & Chief Exec. Officer, Director
Signature: /s/ Suzanne M. Hanlon, Attorney-in-Fact
Stock symbol: ZYNE
Transactions as of: Jan 26, 2022
Transactions value $: $0
Form type: 4
Date filed: 1/28/2022, 03:28 PM
Previous filing: Jun 21, 2021
Next filing: Jun 22, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ZYNE	Common Stock	Award	$0	+120K	+26.06%	$0.00	580K	Jan 26, 2022	Direct	F1
holding	ZYNE	Common Stock						26.6K	Jan 26, 2022	See footnote	F2
holding	ZYNE	Common Stock						13.3K	Jan 26, 2022	See footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ZYNE	Stock Option (right to buy)	Award	$0	+190K		$0.00	190K	Jan 26, 2022	Common Stock	190K	$2.41	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The restricted stock award will fully vest on January 26, 2024, subject to continued employment with the Company through the applicable vesting date.
F2	TUA of Armando Anido and Nancy J. Anido Trusts are controlled by Armando Anido, who has voting and dispositive power with respect to shares held by the trusts.
F3	The stock option vests 25% on the first anniversary of the date of the grant, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company through the applicable vesting date.